M&A · Healthcare · Biological Products, (No Diagnostic Substances)
Roche Holdings Inc to acquire Poseida Therapeutics, Inc.
Announced Nov 25, 2024 · Closed Jan 8, 2025
Deal value$1.00BEV $1.01B
Premium215.0%To unaffected price
EV / Adj. EBITDA—6.7x EV / Revenue
ConsiderationAll cash$9.00 per share
Transaction
- Acquirer
- Roche Holdings Inc
- Target
- Poseida Therapeutics, Inc. (PSTX)
- Buyer type
- Strategic
- Offer price per share
- $9.00
- Enterprise value
- $1.01B
- Status
- Closed Jan 8, 2025
Deal protections
- Break fee (target pays)
- $33.4M · 3.3%
- Reverse fee (buyer pays)
- $33.4M · 3.3%
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Citigroup
- To the target
- Centerview
Sector context · Healthcare
- Comparable deals
- 92 in the prior 24 months
- Premium
- 215.0% vs. 67.0% sector median
- EV / Adj. EBITDA
- Sector median 17.1x
- Break fee
- 3.3% vs. 3.5% sector median
Timeline
- AnnouncedNov 25, 2024
- Tender offerDec 9, 2024
- ClosedJan 8, 2025